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ABSTRACT 
The management of children and adolescents with hypogonadism and in particular the induction 
of puberty in the hypogonadal girl is subject to controversy. Therefore, under the auspices and 
through organization of the Drugs and Therapeutics Committee of the European Society of 
Paediatric Endocrinology (ESPE), an interactive voting session and workshop was held at the 39th 
ESPE Annual Meeting in Brussels to discuss these topics. Common practice in Europe and attitudes 
of pediatric endocrinologists in Europe were questioned and recorded in the 1.5-hour program. We 
now report on some of the results of the questionnaires and discussions of that session to further 
the discussion on and knowledge of current concepts of induction of puberty in the hypogonadal 
girl in Europe. It became clear from the data accumulated here that the start of treatment, the aims 
of therapy and the modalities of how to treat the hypogonadal girl vary amongst pediatric 
endocrinologists in Europe. For example, a chronological age ≥ 11 years was considered 
appropriate for the start of estrogen therapy by 40.4% (out of 188 answers), while 47.8 and 7.5% 
felt that a chronological age ≥ 13 and ≥ 15 years respectively was appropriate. In respect to the 
form and route of estrogen administration, the audience was asked for their common estrogen 
replacement practice: 31.9% used oral 17ß-estradiol treatment, while 10% would prescribe 17ß-
estradiol transdermal patches. Another 12.2% would recommend conjugated estrogens (e.g. 
Premarin®) orally, 4.8% use oral estradiol valerate and 39.3% ethinylestradiol orally. Only 1.8% out 
of 229 physicians answering were undecided. In addition, counseling of patients and their families 
is quite variable and perceptions for example regarding potential pregnancies in affected women 
are also not uniform. In this report the authors do not want to provide their own personal views but 
rather reflect current practice in Europe. It is hoped that a more uniform picture will emerge once 
European and international guidelines on how to treat the girl with hypogonadism will be available 
and even more discussions amongst doctors from different countries have been led.
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Normally puberty in a girl starts when pulsatile release of gonadotropin-releasing hormone (GnRH) 
from the hypothalamus commences. This then triggers the pulsatile secretion of luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. These pituitary hormones 
activate gonadal function. The synthesis and secretion of gonadal steroids subsequently evoke the 
responses in peripheral organs that lead to the development of pubertal changes such as thelarche 
and pubarche. Delay and/or complete absence of these changes due to a late activation of the 
pulse generator of hypothalamic GnRH and/or late and/or reduced release of LH and FSH is known 
as central delay of puberty. GnRH- and LH/FSH-independent delay of pubertal development is 
known as peripheral or primary delayed puberty. While the underlying disorders such as 
hypopituitarism or ovarian failure are well enough diagnosed, the clinical management of 
hypogonadism in girls is still subject to controversy [1–9]. Therefore, under the auspices of the 
Drugs and Therapeutics Committee (DTC) of the European Society of Paediatric Endocrinology 
(ESPE) and through organization of DTC and the Local Organizing Committee of the ESPE Annual 
Meeting in the year 2000, an interactive workshop was held at the 39th Annual Meeting of the 
Society in Brussels to discuss the topic of ‘the induction of puberty in the hypogonadal girl’. 
Common practice in Europe and attitudes of pediatric endocrinologists in Europe were questioned 
and recorded and very actively discussed in the 1.5-hour program. We now report on some of the 
results of the questionnaires and discussions of that session that have been analyzed anonymously 
to further the discussion on and knowledge of current concepts of induction of puberty in the 
hypogonadal girl. 
Methods and Participants 
The data presented here are based upon the responses and information obtained during the 
interactive clinical session on the induction of puberty in the hypogonadal girl that was held in 
Brussels during the 39th ESPE Annual Meeting, September 17–19, 2000. There were 250 pediatric 
endocrinologists who participated in the session actively using the interactive voting system. Of 
the respondents, 46% were younger than 40 years, 46% were between 40 and 60 years old and 8% 
were older than 60 years (total 188 answers). As to the geographical origin of the respondents, 18% 
came from Scandinavia, 20% from the Mediterranean area, 34% were from Benelux, France, 
Germany, Switzerland and Austria, 11% were from Eastern Europe, 8% were from the UK and 
Ireland and 9% came from elsewhere (total 227 answers). Of the participating pediatric 
endocrinologists, 54% were female and 46% were male. The session was based upon a 
computerized questionnaire and an interactive voting system (table 1); the data were graphed and 
recorded using IVS-basic (SysCom®, The Netherlands). 
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Table 1. Questionnaire presented at the 39th ESPE Annual Meeting. 
1 What is your primary aim when prescribing estrogen in a hypogonadal adolescent girl? 
□  Growth spurt (maximal promotion of growth rate) 
□  Final height (minimal promotion of bone maturation) 
□  Peak bone mass 
□  Breast development, feminization 
□  Psychosocial issues 
□  Other 
2 What is the first criterion you consider to propose the start of estrogen therapy in a hypogonadal 
adolescent girl: 
□  A chronological age ≥ 12 years 
□  A chronological age ≥ 13 years 
□  A chronological age ≥ 14 years 
□  A bone age (Greulich-Pyle equivalent) ≥ 12 years 
□  A bone age (Greulich-Pyle equivalent) ≥ 13 years 
□  A bone age (Greulich-Pyle equivalent) ≥ 14 years 
□  A fall in height velocity and/or height below the 3rd centile 
□  The patient request, irrespective of chronological age, bone age and growth 
□  The parent’s request, irrespective of chronological age, bone age and growth 
□  Other 
3 Which form of estrogen and route of administration are you currently using to start ovarian steroid 
substitution in a hypogonadal girl? 
□  17ß-estradiol, orally 
□  17ß-estradiol, transdermal patch 
□  Conjugated estrogens (e.g. Premarin®), orally 
□  Estradiol valerate, orally 
□  Ethinyl estradiol, orally 
□  Other 
4 The most important reason why I elect to use ….. for ovarian substitution, is: 
□  Well-known effects, large experience 
□  Pharmacokinetics, physiological 
□  Registered and reimbursed on the market in my country 
□  New form made available through a research protocol 
□  The best form for safety issues 
□  Other 
5 The most important reason why I elect not to use ….. for ovarian substitution, is: 
□  Not available on the market in my country 
□  Not available at dosages low enough 
□  No evidence that this form is more efficient than the others 
□  No or few published experience (dose-related effects) in hypogonadal adolescent girl 
□  Evidence that this form is metabolically (lipids, ...) less safe than the others 
□  Evidence that this form may increase cancer risk later in life 
□  Other 
□  No opinion 
Questions 4 & 5 are to be separated into subquestions (and subgroups of respondents in the audience) 
according to the answers to question 3. 
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WHAT IS THE PRIMARY AIM OF TREATMENT AND WHAT CRITERION IS CONSIDERED 
TO PROPOSE THE START OF ESTROGEN TREATMENT IN THE HYPOGONADAL 
ADOLESCENT GIRL? 
The question that was asked at the beginning of the session was what the primary aim of estrogen 
treatment was, when an adolescent girl with hypogonadism was presented to the pediatric 
endocrinologist’s practice with the request to be treated for the condition. It was specified that the 
girl in fact would be rather short (< 10th centile). Out of 175 participants answering this question, a 
majority (55.4%) answered that issues of breast development and feminization were of prime 
importance. Another large percentage (17.7%) of the respondents replied that the primary aim 
would be to achieve maximal final height (minimal promotion of bone maturation). Other aims 
were also given by minorities amongst the audience (fig. 1). A rather emotional discussion on the 
issue of psychosocial aims followed the presentation of the answers. 
Fig. 1. Primary aim of estrogen therapy prescribed for a relatively short (height at the 10th centile) 
hypogonadal adolescent girl as stated by European pediatric endocrinologists (n = 175). Responses (%) 
during interactive workshop session on the induction of puberty in the hypogonadal girl held at the 39th 
ESPE Annual Meeting in Brussels, September 19, 1999. Issues of breast development were considered to be 
of the greatest importance for the girl. 
 
 
The majority of the participants felt that chronological age (43.1%) and bone age (37.5%) were the 
criteria tha they considered for the proposition to parents and the hypogonadal adolescent girl to 
start estrogen therapy. Interestingly, 14.4% of the respondents answered that they would follow 
the patient’s request irrespective of chronological age, bone age and growth. A minority (5.1%) felt 
that they considered other criteria for their decision-making. 
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AT WHAT AGE TO START TREATMENT? 
A chronological age ≥ 11 years was considered appropriate for the start of estrogen therapy by 
40.4% (out of 188 answers), while 47.8 and 7.5% felt that a chronological age ≥ 13 and ≥ 15 years 
respectively was appropriate. There were 4.3% who thought that they used an age cut-off different 
from the ones given above (fig. 2). In respect to bone age, 19.4% answered that a bone age ≥ 10 
years (Greulich-Pyle equivalent) was their criterion for when to initiate estrogen replacement, 
while 70.9 and 7.4% respectively responded that a bone age ≥ 12 and ≥ 14 years was their criterion 
to start treatment. 
Fig. 2. Answers (%) of European pediatric endocrinologists (n = 188) during interactive workshop session on 
the induction of puberty in the hypogonadal girl held at the 39th ESPE Annual Meeting in Brussels, 
September 19, 1999 to the question: ‘If you elected to use chronological age as the first criterion to start 
estrogen therapy in a hypogonadal adolescent girl, what age do you consider to propose to start estrogen 
therapy?’ Note the wide age range that is given. 
 
WHAT PREPARATIONS OF ESTROGENS AND WHAT ROUTE OF ADMINISTRATION TO 
CHOSE? 
The form of estrogen and the route of administration varied substantially when the audience was 
asked for their common estrogen replacement practice: 31.9% use oral 17ß-estradiol treatment, 
while 10% prescribe 17ß-estradiol transdermal patches. Another 12.2% would recommend 
conjugated estrogens (e.g. Premarin®) orally, 4.8% use oral estradiol valerate and 39.3% 
ethinylestradiol orally. Only 1.8% out of 229 physicians answering were undecided (fig. 3). 
It is important to note that the most important criterion to select a particular form of treatment 
differed substantially: > 40% said that well-known effects and a large body of experience 
determined their decision-making, while safety issues were only raised by approximately 9%. 
Apparently availability and costs in different countries play an important role as to what 
compound is used for treatment (12.6% out of 230 answers) (fig. 4). 
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Fig. 3. Forms of oestrogen and route of administration currently being used to start ovarian steroid 
substitution in a hypogonadal girl as stated by European Pediatric endocrinologists (n = 229). Responses (%) 
during interactive workshop session on the induction of puberty in the hypogonadal girl held at the 39th 
ESPE Annual Meeting in Brussels, September 19, 1999. Ethinylestradiol and 17ß-estradiol are the most 
commonly used forms. 
 
 
Fig. 4. Most important criterion to select a particular form of treatment for the hypogonadal girl as expressed 
by European pediatric endocrinologists (n = 230). Responses (%) during interactive workshop session on the 
induction of puberty in the hypogonadal girl held at the 39th ESPE Annual Meeting in Brussels, September 
19, 1999. Physiology and individual physician’s experience were considered to be most important. 
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WHAT ARE THE CHANCES OF PREGNANCY? 
A lively discussion spun around pregnancy issues in women with Turner syndrome and in women 
with hypopituitarism. Out of 250 participants answering this topic, 30.8% felt that there was a 
reasonable chance for the woman with Turner syndrome to complete a pregnancy, while 63.2% 
thought that there was a poor chance for her to complete a pregnancy. In contrast, 78.5% 
responded that they would inform the hypopituitary girl that there was a reasonable chance for 
her to complete a pregnancy, while 16.2% would advise her that there was a poor chance to 
complete a pregnancy. Surprisingly, 5.3% would not know and would be unable to give 
information about the prospects for pregnancy in a hypopituitary girl. 
Discussion 
This interaction session on the induction of puberty in the hypogonadal girl brought together some 
250 European pediatric endocrinologists to discuss views and attitudes and common clinical 
practice on the topic. It became apparent that while in many respects there were majority votes, 
many questions were subject to controversy. This survey was not intended to become a consensus 
conference or issue guidelines but rather to evaluate and summarize common clinical practice in 
Europe and attitudes of pediatric endocrinologists in Europe. It is clear that while it is important to 
know about physicians’ attitudes, one should also know about the perception of height, 
acceptance of therapy and psychosocial functioning in the hypogonadal girls and their families in 
different populations [10–14]. Only few such surveys involving the patients themselves have been 
conducted [11]. Adjustments of estrogen and growth hormone doses over time [10, 12] have been 
proposed. Age at which therapies should start is seen under different aspects: cultural, metabolic, 
auxologic and psychosocial issues prevail while even personal views and perceptions do influence 
a physician’s recommendations [12–18]. This overall view became apparent during the lively 
discussions at the meeting. Since there are trends towards earlier pubertal development in healthy 
populations in Europe [13, 15, 17, 18], therapeutic strategies are most likely to change over time as 
personal views and physicians’ perceptions do. However, there are of course basic principles that 
the responsible physician should adhere to: it should therefore be mandatory that drug treatment 
strategies are based upon knowledge of safety and physiology issues rather than on monetary 
prizes, customs and personal beliefs. 
Conclusion 
We have reported on some of the results of the questionnaires and discussions of an interactive 
voting session on the induction of puberty in the hypogonadal girl. This session had been 
organized under the auspices and through organization of the DTC of the ESPE at the 39th Annual 
Meeting of the Society in Brussels. Common practice in Europe and attitudes of pediatric 
endocrinologists in Europe vary. It is hoped that a more uniform picture will emerge once 
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European and international guidelines on how to treat the girl with hypogonadism will be available 
and even more discussions amongst doctors from different countries have been led. It is hoped 
that the results of the questionnaires and discussions of the session will actually further the 
discussion on and knowledge of current concepts of induction of puberty in the hypogonadal girl 
in Europe. 
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